Verastem Oncology received FDA approval for its combination therapy and published the trial results in the journal JCO.
2 reports, 1 independent
Updated Jul 12
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Verastem Oncology received FDA approval for its combination therapy and published the trial results in the journal JCO.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Verastem Oncology announced a clinical trial in Boston.Sub-event
Verastem Oncology received FDA approval for its combination therapy and published the trial results in the journal JCO.1 source
Keep exploring
The entities involved
- FDA
-
Verastem Oncology
Pharmaceutical company in Masachussets, United States
Nothing else this week.
-
JCO
Japanese nuclear fuel cycle company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- Business WireVerastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer
- Unknown outlet